Evidence map›Paper›PMID 37164921›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2023

Efficacy and safety of avatrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: A real-world data evaluation on 14 cases.

Enyi Liu, Peng Fang, Hongya Xin, Shujun Li, Yi Liu, Yajing Xu, Yan Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Enyi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008. liuenyi@csu.edu.cn.
Peng FangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Hongya XinDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Shujun LiDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yajing XuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yan ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008. yanchen2018@csu.edu.cn.
Central South University · CN

Funding

the Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province CXPJJH12000009-102the National Natural Science Foundation 81974002the Natural Science Foundation of Hunan Province 2021JJ41006the Translational Research Grant of NCRCH 2021WWC02
6 · The paper itself

Abstract

objectivesThrombocytopenia following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common and serious complication that leads to an increased risk of bleeding and poor prognosis. Traditional strategies consist of platelet transfusion, glucocorticoid therapy, intravenous human immunoglobulin, recombinant human thrombopoietin injection, and CD34

methodsFourteen patients with thrombocytopenia after allo-HSCT underwent avatrom-bopag treatment from September 2020 to September 2021 were retrospectively studied. Of these patients, 8 patients had delayed platelet engraftment (DPE) and 6 cases had secondary failure of platelet recovery (SFPR). The efficacy and safety of the treatment and the survival of the patients were assessed.

resultsThe median treatment time of avatrombopag was 34 days, and no patients stopped treatment due to adverse reactions or drug intolerance. Compared with the treatment before, the levels of platelet count, megakaryocytes, and hemoglobin in patients were significantly increased (

conclusionsAvatrombopag is effective on increasing platelet counts in patients with thrombocytopenia after allo-HSCT, with a good safety profile. It is a suitable therapeutic option for thrombocytopenia after allo-HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationThrombocytopeniaBlood PlateletsHumansRetrospective StudiesThiazolesThiophenesavatrombopagThiazolesThiophenesallogeneic hematopoietic stem cell transplantationavatrombopagthrombocytopeniathrombopoietin

Identifiers

PMID37164921
PMCPMC10930078
OpenAlexW4376132887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.